Penpulimab-kcqx is ahumanized IgG1 monoclonal antibody and programmed cell death protein 1 (PD-1) inhibitordeveloped by
Akeso, Inc.Medical Indications and Approvals
- Nasopharyngeal Carcinoma (NPC): Approved by the U.S. FDA in April 2025 as penpulimab-kcqx for adult non-keratinizing nasopharyngeal carcinoma in two main settings:
- First-line treatment: Given intravenously in combination with cisplatin or carboplatin and gemcitabine for recurrent or metastatic disease.
- Single-agent treatment: Used alone for metastatic disease that has progressed following platinum-based chemotherapy and at least one other prior line of therapy.
- International Status: Also approved in China (marketed under the brand name Anike) for recurrent or metastatic nasopharyngeal carcinoma and locally advanced/metastatic squamous non-small cell lung cancer.